Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Given Consensus Recommendation of “Hold” by Brokerages

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) has received an average rating of “Hold” from the five research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $40.00.

A number of analysts have issued reports on SNSE shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Friday, April 24th. Leerink Partners started coverage on shares of Sensei Biotherapeutics in a report on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective for the company. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Citigroup started coverage on shares of Sensei Biotherapeutics in a report on Friday. They issued a “buy” rating for the company.

Insider Activity at Sensei Biotherapeutics

In other news, major shareholder Millennium Management Llc bought 15,321 shares of the company’s stock in a transaction dated Friday, March 27th. The stock was bought at an average cost of $26.61 per share, for a total transaction of $407,691.81. Following the transaction, the insider owned 142,360 shares of the company’s stock, valued at $3,788,199.60. This represents a 12.06% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders have purchased 46,980 shares of company stock valued at $1,341,669 and have sold 23,067 shares valued at $704,439. Insiders own 23.20% of the company’s stock.

Institutional Investors Weigh In On Sensei Biotherapeutics

Large investors have recently modified their holdings of the business. Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics during the 1st quarter worth $22,758,000. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics during the 1st quarter worth $4,188,000. Bank of America Corp DE raised its holdings in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares in the last quarter. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Stock Down 0.1%

NASDAQ SNSE opened at $17.56 on Friday. The company has a market capitalization of $23.53 million, a P/E ratio of -0.12 and a beta of -0.18. Sensei Biotherapeutics has a 12-month low of $5.25 and a 12-month high of $36.76. The firm has a 50-day moving average price of $27.93 and a two-hundred day moving average price of $18.17.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). Equities analysts expect that Sensei Biotherapeutics will post -2.77 EPS for the current year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.